Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 101Carcinoma, Non-Small-Cell Lung 88Carcinoma, Renal Cell 54Neoplasm Metastasis 37Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 32Carcinoma, Hepatocellular 32Lung Neoplasms 31Hodgkin Disease 25Neoplasms 24Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Carcinoma, Transitional Cell 20Breast Neoplasms 19Stomach Neoplasms 17Brain Neoplasms 17Prostatic Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 15Multiple Myeloma 14Head and Neck Neoplasms 14Esophageal Neoplasms 14Glioblastoma 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Neuroendocrine Tumors 10Lymphoma 10Recurrence 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone Sensitive Prostate Cancer × Nivolumab × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡